These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
93 related articles for article (PubMed ID: 1865340)
1. Development of aqueous parenteral formulations for carbamazepine through the use of modified cyclodextrins. Brewster ME; Anderson WR; Estes KS; Bodor N J Pharm Sci; 1991 Apr; 80(4):380-3. PubMed ID: 1865340 [TBL] [Abstract][Full Text] [Related]
2. New injectable aqueous carbamazepine solution through complexing with 2-hydroxypropyl-beta-cyclodextrin: tolerability and pharmacokinetics after intravenous injection in comparison to a glycofurol-based formulation. Löscher W; Hönack D; Richter A; Schulz HU; Schürer M; Düsing R; Brewster ME Epilepsia; 1995 Mar; 36(3):255-61. PubMed ID: 7614909 [TBL] [Abstract][Full Text] [Related]
3. Effect of hydroxypropyl beta-cyclodextrin on drug solubility in water-propylene glycol mixtures. Chang RK; Shojaei AH Drug Dev Ind Pharm; 2004 Mar; 30(3):297-302. PubMed ID: 15109029 [TBL] [Abstract][Full Text] [Related]
4. Intravenous carbamazepine: comparison of different parenteral formulations in a mouse model of convulsive status epilepticus. Löscher W; Hönack D Epilepsia; 1997 Jan; 38(1):106-13. PubMed ID: 9024191 [TBL] [Abstract][Full Text] [Related]
5. Development of parenteral formulation for a novel angiogenesis inhibitor, CKD-732 through complexation with hydroxypropyl-beta-cyclodextrin. Kim JH; Lee SK; Ki MH; Choi WK; Ahn SK; Shin HJ; Hong CI Int J Pharm; 2004 Mar; 272(1-2):79-89. PubMed ID: 15019071 [TBL] [Abstract][Full Text] [Related]
6. Oversaturated solutions of drug in hydroxypropylcyclodextrins: parenteral preparation of pancratistatin. Torres-Labandeira JJ; Davignon P; Pitha J J Pharm Sci; 1991 Apr; 80(4):384-6. PubMed ID: 1865341 [TBL] [Abstract][Full Text] [Related]
7. Inclusion complexation of the sunscreen agent 2-ethylhexyl-p-dimethylaminobenzoate with hydroxypropyl-beta-cyclodextrin: effect on photostability. Scalia S; Villani S; Casolari A J Pharm Pharmacol; 1999 Dec; 51(12):1367-74. PubMed ID: 10678490 [TBL] [Abstract][Full Text] [Related]
8. Intravenous and oral pharmacokinetic evaluation of a 2-hydroxypropyl-beta-cyclodextrin-based formulation of carbamazepine in the dog: comparison with commercially available tablets and suspensions. Brewster ME; Anderson WR; Meinsma D; Moreno D; Webb AI; Pablo L; Estes KS; Derendorf H; Bodor N; Sawchuk R; Cheung B; Pop E J Pharm Sci; 1997 Mar; 86(3):335-9. PubMed ID: 9050802 [TBL] [Abstract][Full Text] [Related]
9. Influence of hydrophilic polymers on the complexation of carbamazepine with hydroxypropyl-β-cyclodextrin. Medarević D; Kachrimanis K; Djurić Z; Ibrić S Eur J Pharm Sci; 2015 Oct; 78():273-85. PubMed ID: 26255049 [TBL] [Abstract][Full Text] [Related]
10. Effect of water-soluble polymers on naproxen complexation with natural and chemically modified beta-cyclodextrins. Faucci MT; Mura P Drug Dev Ind Pharm; 2001 Oct; 27(9):909-17. PubMed ID: 11763468 [TBL] [Abstract][Full Text] [Related]
11. Bile acid and sterol solubilization in 2-hydroxypropyl-beta-cyclodextrin. De Caprio J; Yun J; Javitt NB J Lipid Res; 1992 Mar; 33(3):441-3. PubMed ID: 1569391 [TBL] [Abstract][Full Text] [Related]
12. Effect of SBE7-beta-cyclodextrin complexation on carbamazepine release from sustained release beads. Smith JS; Macrae RJ; Snowden MJ Eur J Pharm Biopharm; 2005 May; 60(1):73-80. PubMed ID: 15848059 [TBL] [Abstract][Full Text] [Related]
13. Development of a non-surfactant formulation for alfaxalone through the use of chemically-modified cyclodextrins. Brewster ME; Estes KS; Bodor N J Parenter Sci Technol; 1989; 43(6):262-5. PubMed ID: 2600731 [TBL] [Abstract][Full Text] [Related]
14. Hydroxypropyl-beta-cyclodextrin increases aqueous solubility and stability of anandamide. Jarho P; Urtti A; Järvinen K; Pate DW; Järvinen T Life Sci; 1996; 58(10):PL 181-5. PubMed ID: 8602110 [TBL] [Abstract][Full Text] [Related]
15. Inclusion complexation of diazepam with different cyclodextrins in formulations for parenteral use. Holvoet C; Heyden YV; Plaizier-Vercammen J Pharmazie; 2005 Aug; 60(8):598-603. PubMed ID: 16124403 [TBL] [Abstract][Full Text] [Related]
16. [Effect of temperature on drug solubility in complex formation of flubendazole and 2-hydroxypropyl-beta-cyclodextrin]. Vetchý D; Rabisková M; Sucman E Ceska Slov Farm; 2000 Sep; 49(5):239-41. PubMed ID: 11077730 [TBL] [Abstract][Full Text] [Related]
17. Preparation and characterization of the inclusion complex of furosemide with hydroxypropyl-beta-cyclodextrin. Vlachou M; Papaïoannou G J Biomater Appl; 2003 Jan; 17(3):197-206. PubMed ID: 12614084 [TBL] [Abstract][Full Text] [Related]
18. [Solubilization and complexation of the antileukotrienic drug Quinlukast in aqueous solutions of cyclodextrins]. Kopecký F; Kopecká B Ceska Slov Farm; 2005 May; 54(3):137-40. PubMed ID: 15945461 [TBL] [Abstract][Full Text] [Related]
19. [Dissolution of nimodipine in an aqueous solution of hydroxyethyl-beta-cyclodextrin and a review of solubility of nimodipine with cyclodextrins]. Kopecký F; Kopecká B; Kaclík P Ceska Slov Farm; 2003 Jan; 52(1):33-8. PubMed ID: 12685332 [TBL] [Abstract][Full Text] [Related]
20. The use of chemically modified cyclodextrins in the development of formulations for chemical delivery systems. Brewster ME; Loftsson T Pharmazie; 2002 Feb; 57(2):94-101. PubMed ID: 11878196 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]